Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.67 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831719 | 0.85 | IGF1R (0.65) | IGF1RINSRPLK4PAK4 | |
| SCHEMBL17565561 | 0.82 | IGF1R (0.48) | IGF1RINSRPLK4PAK4 | |
| SCHEMBL15814881 | 0.81 | IGF1R (0.48) | IGF1RINSRPLK4PAK4 | |
| SCHEMBL15815782 | 0.78 | IGF1R (0.67) | IGF1RINSR | |
| SCHEMBL18836699 | 0.77 | IGF1R (0.63) | IGF1RINSR | |
| SCHEMBL16540730 | 0.76 | IGF1R (0.64) | IGF1RINSRNTRK1 | |
| SCHEMBL17397440 | 0.75 | IGF1R (0.57) | IGF1RINSR | |
| SCHEMBL17397403 | 0.74 | IGF1R (0.67) | IGF1RINSR | |
| SCHEMBL2120951 | 0.73 | NTRK1 (0.58) | IGF1RPLK4PAK4NTRK1PIK3C3 | |
| SCHEMBL17397437 | 0.72 | IGF1R (0.55) | IGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2016003827-A2 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137410-A1 | FUSED CYCLOALKYL-PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, DTYMK, TK1 | IGF1R 2770/4885INSR 2102/4885PLK4 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.